PlainPharmaWatch

CMS Open Payments · Tool

Ethicon Inc. vs Sumitomo Pharma Co., Ltd.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Sumitomo Pharma Co., Ltd. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 2,292, versus 132 for the other company. Its single largest recorded recipient represents 36.9% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Ethicon Inc.
HHI 132 · top recipient 7.6%
Ranked #1,643 of 1,838 companies by HHI
Sumitomo Pharma Co., Ltd.
HHI 2,292 · top recipient 36.9%
Ranked #696 of 1,838 companies by HHI

Payment Overview

Company A

Ethicon Inc.

Total Payments
$3.5M
% of Industry
0.0%
Transactions
3,132
Avg per Transaction
$1.1K
Recipients
2,774
Avg per Recipient
$1.3K
Payment Types
5
Top Payment Type
Consulting Fee
Total Payments
$3.5M
% of Industry
0.0%
Transactions
94
Avg per Transaction
$37.3K
Recipients
89
Avg per Recipient
$39.4K
Payment Types
5
Top Payment Type
Charitable Contribution

Highlighted values indicate the higher figure for each metric.

Total payments compared

Ethicon Inc. vs Sumitomo Pharma Co., Ltd. - total reported payments in CMS Open Payments PY2024

Ethicon Inc.$3.5MSumitomo Pharma Co., Ltd.$3.5M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Ethicon Inc.

Consulting Fee $1.9M

85.5%

Travel and Lodging $174.3K

7.9%

Food and Beverage $70.3K

3.2%

Space Rental or Facility Fees $57.8K

2.6%

Royalty or License $17.7K

0.8%

Sumitomo Pharma Co., Ltd.

Charitable Contribution $44.9K

36.9%

Travel and Lodging $40.9K

33.5%

Honoraria $21.0K

17.2%

Consulting Fee $14.5K

11.9%

Food and Beverage $555.57

0.5%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Ethicon Inc.

  1. 1

    KEITH C KIM

    $167,965.99 · 115 txns

  2. 2

    COLLIN E M BRATHWAITE

    $50,246.16 · 33 txns

  3. 3

    ERIK B WILSON

    $49,249.68 · 26 txns

  4. 4

    EDUARDO PARRA DAVILA

    $40,921.37 · 32 txns

  5. 5

    EUGENE O DICKENS

    $37,664.77 · 24 txns

Sumitomo Pharma Co., Ltd.

  1. 1

    Massachusetts Eye And Ear Infirmary

    $44,947.00 · 1 txns

  2. 2

    NAVAL G DAVER

    $31,482.90 · 17 txns

  3. 3

    ROHIT KULKARNI

    $14,830.31 · 9 txns

  4. 4

    AKIRA SAWA

    $7,021.03 · 33 txns

  5. 5

    John M. Kane

    $6,983.57 · 10 txns

Summary Comparison

Metric Ethicon Inc. Sumitomo Pharma Co., Ltd.
Total Payments $3.5M $3.5M
% of Industry Total 0.0% 0.0%
Transaction Count 3,132 94
Avg per Transaction $1.1K $37.3K
Recipient Count 2,774 89
Avg per Recipient $1.3K $39.4K
Payment Type Count 5 5
Top Payment Type Consulting Fee Charitable Contribution

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.